Payment overview · 2025
General Payments
$395.67
20 reported records · 7 companies
Healthcare provider profile · identity verified
Brian Mccarver, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, TN · NPI 1861428898
Verified facts
What the public records show
CMS Open Payments records show Brian Mccarver, M.D. received $395.67 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 40.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $158.82 | 40.1% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.12 | 24.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.59 | 12.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.85 | 7.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.19 | 7.1% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.38 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.72 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.67 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $145.51 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.77 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.59 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.62 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.85 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.19 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
57 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 521 | 137 |
| Losartan Potassium | Losartan Potassium | 513 | 133 |
| Gabapentin | Gabapentin | 410 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 116 |
| Simvastatin | Simvastatin | 339 | 79 |
| Furosemide | Furosemide | 316 | 99 |
| Metformin Hcl | Metformin Hcl | 279 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 67 |
| Lisinopril | Lisinopril | 276 | 67 |
| Prednisone | Prednisone | 272 | 167 |
| Levothyroxine Sodium | Levothyroxine Sodium | 267 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 259 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 242 | 40 |
| Alprazolam | Alprazolam | 240 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 60 |
| Meloxicam | Meloxicam | 220 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 48 |
| Eliquis | Apixaban | 183 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 45 |
| Glimepiride | Glimepiride | 180 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 40 |
| Carvedilol | Carvedilol | 167 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 51 |
| Potassium Chloride | Potassium Chloride | 154 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 149 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 33 |
| Ozempic | Semaglutide | 128 | 25 |
| Azithromycin | Azithromycin | 122 | 91 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 118 | 32 |
| Trazodone Hcl | Trazodone Hcl | 118 | 29 |
| Montelukast Sodium | Montelukast Sodium | 117 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 45 |
| Celecoxib | Celecoxib | 116 | 31 |
| Tramadol Hcl | Tramadol Hcl | 113 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 77 |
| Pregabalin | Pregabalin | 104 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 102 | 13 |
| Clonidine Hcl | Clonidine Hcl | 98 | 24 |
| Fluconazole | Fluconazole | 88 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 26 |
| Allopurinol | Allopurinol | 82 | 21 |
| Nystatin | Nystatin | 82 | 34 |
| Lorazepam | Lorazepam | 77 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 76 | 12 |
| Donepezil Hcl | Donepezil Hcl | 74 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 11 |
| Benazepril Hcl | Benazepril Hcl | 70 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 15 |
| Cephalexin | Cephalexin | 63 | 51 |
| Farxiga | Dapagliflozin Propanediol | 63 | 17 |
| Sertraline Hcl | Sertraline Hcl | 62 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 20 |
| Linzess | Linaclotide | 58 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 57 | 47 |
| Atenolol | Atenolol | 56 | suppressed |
| Jardiance | Empagliflozin | 56 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 54 | 54 |
| Famotidine | Famotidine | 53 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 11 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Promethazine Hcl | Promethazine Hcl | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 27 |
| Meclizine Hcl | Meclizine Hcl | 47 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 11 |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 13 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Mupirocin | Mupirocin | 45 | 17 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Lovastatin | Lovastatin | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 17 |
| Finasteride | Finasteride | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 16 |
| Levofloxacin | Levofloxacin | 39 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 13 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 23 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 16 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ramipril | Ramipril | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Digoxin | Digoxin | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.67 · 20 records | Novo Nordisk Inc | AREXVY, BEXSERO, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, JATENZO, Ozempic, Rybelsus, SHINGRIX, VOQUEZNA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error